{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Group+A%3A+Saline+Group&page=13", "query": { "intervention": "Group A: Saline Group", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 1199, "total_pages": 120, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Group+A%3A+Saline+Group&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Group+A%3A+Saline+Group&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T01:49:08.153Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03197870", "title": "The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nonproliferative Diabetic Retinopathy" ], "interventions": [ { "name": "AKB-9778", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EyePoint Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 167, "start_date": "2017-06-09", "completion_date": "2019-02-09", "has_results": true, "last_update_posted_date": "2023-06-27", "last_synced_at": "2026-10-15T01:49:08.153Z", "location_count": 53, "location_summary": "Phoenix, Arizona • Arcadia, California • Bakersfield, California + 47 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03197870" }, { "nct_id": "NCT05891613", "title": "A Study of Liposomal Bupivacaine Versus 0.25% Bupivacaine Hydrochloride Post Breast Reduction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Breast Reduction" ], "interventions": [ { "name": "Bupivacaine Hydrochloride", "type": "DRUG" }, { "name": "Liposomal Bupivacaine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "FEMALE", "summary": "18 Years to 70 Years · Female only" }, "enrollment_count": 32, "start_date": "2024-01-24", "completion_date": "2025-10-06", "has_results": false, "last_update_posted_date": "2025-12-15", "last_synced_at": "2026-10-15T01:49:08.153Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05891613" }, { "nct_id": "NCT00261274", "title": "Safety Study of ECO Conversion System For Red Blood Cells.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anemia" ], "interventions": [ { "name": "A-ECO", "type": "BIOLOGICAL" }, { "name": "Saline", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Velico Medical", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 60, "start_date": "2005-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2020-05-27", "last_synced_at": "2026-10-15T01:49:08.153Z", "location_count": 6, "location_summary": "New Haven, Connecticut • Minneapolis, Minnesota • Albuquerque, New Mexico + 3 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00261274" }, { "nct_id": "NCT02974010", "title": "Sequential Therapy for the Treatment of Severe Bipolar Depression.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bipolar Depression", "Suicidal Ideas", "Suicidal Ideation", "Suicide, Attempted" ], "interventions": [ { "name": "NRX-101 Oral Capsule", "type": "DRUG" }, { "name": "Lurasidone Oral Capsule", "type": "DRUG" }, { "name": "Ketamine Intravenous Infusion", "type": "DRUG" }, { "name": "Saline Solution Intravenous Infusion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NeuroRx, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 22, "start_date": "2018-01-15", "completion_date": "2019-11-20", "has_results": true, "last_update_posted_date": "2021-05-25", "last_synced_at": "2026-10-15T01:49:08.153Z", "location_count": 4, "location_summary": "Birmingham, Alabama • Fort Lauderdale, Florida • Charlotte, North Carolina + 1 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02974010" }, { "nct_id": "NCT01851694", "title": "Beta-cell Response to Incretin Hormones in Cystic Fibrosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cystic Fibrosis", "Pancreatic Insufficiency" ], "interventions": [ { "name": "GLP-1", "type": "DRUG" }, { "name": "GIP", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2013-05", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-01-14", "last_synced_at": "2026-10-15T01:49:08.153Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01851694" }, { "nct_id": "NCT01482221", "title": "A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "AZD6765 iv", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 542, "start_date": "2011-12-16", "completion_date": "2013-08-26", "has_results": true, "last_update_posted_date": "2017-04-11", "last_synced_at": "2026-10-15T01:49:08.153Z", "location_count": 33, "location_summary": "Chino, California • Lond Beach, California • San Diego, California + 30 more", "locations": [ { "city": "Chino", "state": "California" }, { "city": "Lond Beach", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Heaven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01482221" }, { "nct_id": "NCT02668952", "title": "Fluid Chloride and AKI in Cardiopulmonary Bypass", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Kidney Injury" ], "interventions": [ { "name": "0.9% Normal Saline (0.9% Sodium Chloride) injection", "type": "DRUG" }, { "name": "Isolyte S injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of New Mexico", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2016-01", "completion_date": "2018-02", "has_results": true, "last_update_posted_date": "2018-05-14", "last_synced_at": "2026-10-15T01:49:08.153Z", "location_count": 1, "location_summary": "Albuquerque, New Mexico", "locations": [ { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT02668952" }, { "nct_id": "NCT06995352", "title": "Liposomal Bupivacaine Versus Continuous Peripheral Nerve Blocks for Analgesia Following Ankle Surgery", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Moderate-to-severely Painful Ankle Surgery" ], "interventions": [ { "name": "Popliteal nerve block including liposomal bupivacaine", "type": "DRUG" }, { "name": "Adductor canal nerve block including liposomal bupivacaine", "type": "DRUG" }, { "name": "Continuous popliteal nerve block with normal saline", "type": "DRUG" }, { "name": "Popliteal nerve block with exclusively unencapsulated bupivacaine", "type": "DRUG" }, { "name": "Adductor canal nerve block with exclusively unencapsulated bupivacaine", "type": "DRUG" }, { "name": "Continuous popliteal nerve block with unencapsulated bupivacaine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2025-06-23", "completion_date": "2027-06-22", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-15T01:49:08.153Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06995352" }, { "nct_id": "NCT05413668", "title": "First in Human Study of RVP-001, a New Manganese Based MRI Contrast Agent", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "RVP-001", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Reveal Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 32, "start_date": "2022-05-18", "completion_date": "2022-08-22", "has_results": true, "last_update_posted_date": "2025-04-22", "last_synced_at": "2026-10-15T01:49:08.153Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05413668" }, { "nct_id": "NCT06309368", "title": "Ostomy Primary Closure With 0.1% Betaine/Polyhexanide Wound Irrigation Compared to Pursestring Closure", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Surgical Site Infection", "Wound Surgical", "Colorectal Disorders" ], "interventions": [ { "name": "Primary Ostomy Closure with 0.1% Betaine/0.1% Polyhexanide Wound Irrigation", "type": "DRUG" }, { "name": "Pursestring Closure", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Nevada, Las Vegas", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2024-03-14", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2025-06-02", "last_synced_at": "2026-10-15T01:49:08.153Z", "location_count": 1, "location_summary": "Las Vegas, Nevada", "locations": [ { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT06309368" } ] }